Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 10, 2022

SELL
$4.65 - $7.43 $12,206 - $19,503
-2,625 Reduced 0.11%
2,440,372 $15 Million
Q2 2022

Aug 12, 2022

SELL
$4.82 - $7.7 $154,264 - $246,438
-32,005 Reduced 1.29%
2,442,997 $12.9 Million
Q1 2022

May 16, 2022

BUY
$6.0 - $16.98 $66,162 - $187,238
11,027 Added 0.45%
2,475,002 $16.2 Million
Q4 2021

Feb 14, 2022

BUY
$15.19 - $29.33 $1.78 Million - $3.45 Million
117,457 Added 5.01%
2,463,975 $40.4 Million
Q3 2021

Nov 12, 2021

BUY
$27.35 - $37.28 $4,321 - $5,890
158 Added 0.01%
2,346,518 $68.1 Million
Q2 2021

Aug 16, 2021

BUY
$26.5 - $38.23 $1.45 Million - $2.1 Million
54,871 Added 2.39%
2,346,360 $84.2 Million
Q1 2021

May 14, 2021

BUY
$29.83 - $56.81 $13.7 Million - $26.1 Million
459,928 Added 25.11%
2,291,489 $72.4 Million
Q4 2020

Feb 12, 2021

BUY
$39.12 - $54.99 $4.41 Million - $6.21 Million
112,843 Added 6.57%
1,831,561 $86.6 Million
Q3 2020

Nov 13, 2020

BUY
$29.21 - $46.58 $11.7 Million - $18.7 Million
400,632 Added 30.39%
1,718,718 $80.1 Million
Q2 2020

Aug 12, 2020

BUY
$33.67 - $40.0 $13.9 Million - $16.5 Million
413,080 Added 45.64%
1,318,086 $47.5 Million
Q1 2020

May 13, 2020

BUY
$24.28 - $49.8 $19.8 Million - $40.5 Million
814,101 Added 895.55%
905,006 $32.1 Million
Q4 2019

Feb 12, 2020

BUY
$24.84 - $45.46 $1.84 Million - $3.36 Million
74,007 Added 437.96%
90,905 $4.13 Million
Q3 2019

Nov 12, 2019

BUY
$22.78 - $29.08 $384,936 - $491,393
16,898 New
16,898 $419,000

Others Institutions Holding ZYME

About Zymeworks Inc.


  • Ticker ZYME
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,694,400
  • Market Cap $949M
  • Description
  • Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...
More about ZYME
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.